Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day S, Acquah K, Lee P, Mruthyunjaya P, et al. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
2011
Authors
Day S, Acquah K, Lee P, Mruthyunjaya P, et al.
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • An estimated 51,593 Americans ages 40-49 are blind. That grows to 86,623 at ages 75-79 and just under 1 million for ages 80+.  
  • Americans 65+ that have severe visual impairment
    6.5 million Americans over the age of 65 have severe visual impairment that threatens to limit their mobility, independence, and quality of life.  
  • Quality of life of diabetic retinopathy patients
    A study evaluating quality of life using utility values, found that diabetic retinopathy patients with best-corrected visual acuity of 20/20 and 20/25, were willing to trade 15% of their remaining…  
  • The number of Medicare beneficiaries newly diagnosed with wet age-related macular degeneratino (AMD) more than doubled between 1994 and 2006.  
  • Prevalence of Age-Related Eye Disease by Gender and age